# MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma

> **NCT02551055** · PHASE1 · TERMINATED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma

## Interventions

- **DRUG:** MLN1117
- **DRUG:** TAK-659
- **DRUG:** Alisertib
- **DRUG:** Paclitaxel
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02551055
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10-15
- **Primary completion:** 2017-02-17
- **Final completion:** 2017-02-17
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Business Decision; No Safety Or Efficacy Concerns.
- **Last updated:** 2019-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02551055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02551055, "MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02551055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*